Cystic fibrosis drug company to re-engage with HSE on price of Orkambi

Vertex has responded to calls from the HSE with a view to re-engage on the pricing of cystic fibrosis drug Orkambi.

Cystic fibrosis drug company to re-engage with HSE on price of Orkambi
Wed, 07 Dec, 2016 - 18:40

Vertex has responded to calls from the HSE with a view to re-engage on the pricing of cystic fibrosis drug Orkambi.

In a statement this evening, Minister for Health Simon Harris said he is pleased to learn that Vertex has responded to the HSE.

You have reached your article limit. Already a subscriber? Sign in

Continue reading for €5

Unlock unlimited access and exclusive benefits

CONNECT WITH US TODAY

Whatsapp logo

WHATSAPP

Newsletter logo

NEWSLETTERS

Notification logo

NOTIFICATIONS

Be the first to know the latest news and updates

More in this section

Domestic abuse Woman more likely to feel downhearted or depressed than men, new survey shows
Five sites linked to majority of odour complaints as EPA steps up enforcement Five sites linked to majority of odour complaints as EPA steps up enforcement
New National ChildrenÂ’s Hospital to cost more than 1.43 billion euro Development board of National Children's Hospital to seek damages due to BAM delays
CourtsCystic FibrosisOrkambi
<p>IFI is facing a Workplace Relations Commission case brought by former chief executive Francis O’Donnell (pictured), who alleges he was blackmailed by a sitting senator in relation to his suspension in 2002 of the brother of IFI’s former chair, Fintan Gorman.</p>

Inland Fisheries Ireland admits to 'ongoing and uphill struggle' to win back public trust

READ NOW

Lunchtime News

Newsletter

Keep up with stories of the day with our lunchtime news wrap and important breaking news alerts.

Latest

Most Read

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited